Developing a biosimilar medicine requires significant expertise to ensure that it is “highly similar” to the reference biologic with no clinically meaningful differences in the safety profile, efficacy, or potency. This means extensively identifying and comparing the structural and functional properties of the biosimilar, using state-of-the-art technology. For a biosimilar, comparative structural and functional characterization will provide the greatest contribution to clinical predictability.